Analysis of potential interactions between warfarin and prescriptions in Estonian outpatients aged 50 years or more

Maia GAVRONSKI, Sirpa HARTIKAINEN, Alexander ZHARKOVSKY.

Original Research

ABSTRACT

In Estonia, warfarin is widely prescribed by general practitioners to prevent and treat thromboembolic diseases. To date, there has been no systematic analysis of the potential risk of warfarin interactions with other drugs in the outpatient population.

Objective: The aim of the study was to analyze the incidence of potential interactions in prescription schemes in Estonia in a cohort of outpatients receiving warfarin treatment.

Methods: The retrospective study population included 203,646 outpatients aged 50 years or older of whom 7,175 received warfarin therapy. Patients who had used at least one prescription drug for a minimum period of 7 days concomitantly with warfarin were analyzed. Potential drug interactions were analyzed using Epocrates online, Stockley’s Drug Interactions and domestic drug interaction databases.

Results: The average number of drugs used concomitantly with warfarin was 4.8 (SD=1.9) (males: 4.7 SD=2.0, females: 4.9 SD=2.0). No potential interactions in treatment regimens were found in 38% of patients, one potential interaction was observed in 29% and two or more potential interactions were observed in 33% of patients. The mean number of all potential interactions was 1.2 per patient and about the same in men and women. Potential interactions were associated with the number of drugs. Warfarin-related interactions were detected in 57% of patients, and the number of interactions related to warfarin per patient varied from 1 to 5. Most frequent were use of warfarin with NSAIDs (14%), followed by simvastatin (9%) and amiodarone (7%).

Conclusion: This study shows that 57% of outpatients in Estonia receiving warfarin have drugs potentially interacting with warfarin in their treatment schemes. Most interactions (14%) with warfarin are associated with the prescription of NSAIDs.

Keywords: Warfarin. Drug Interactions. Outpatients. Estonia.
INTRODUCTION

Thromboembolic diseases including stroke and venous thromboembolism are associated with a significant increase in mortality and morbidity. These conditions primarily affect older patients with atrial fibrillation, and this group of patients ultimately requires effective and well-tolerated long-term therapy. Currently, the most commonly used drug for the prevention of thromboembolic diseases is warfarin. Warfarin plays a significant role in anticoagulant therapy due to the availability of an oral formulation and its low cost and efficacy. Although warfarin has been used in clinical practice for more than 60 years, it is still associated with several adverse reactions/events due to its narrow therapeutic index, patient compliance, high inter-individual variability, and interactions with many other drugs.

Warfarin is one of the top three drugs (alongside insulin and digoxin) that are most commonly associated with severe drug-related complications. The main reason for this is the variety of interactions (about 400) with other drugs. Recent data suggest that warfarin drug interactions might be a major source of the bleeding events in patients receiving anticoagulant treatment. Warfarin interactions can vary from theoretical (clinically insignificant) to severe life-threatening interactions. The most frequent clinical manifestation of the interactions is bleeding, which can vary from superficial ecchymoses to severe haemorrhage in the gastrointestinal tract or brain. It was reported that about 70% of warfarin interactions are associated with an increase in its effects, while only 15% are reported to reduce its effects. Elderly patients are more commonly affected by the adverse effects of warfarin than younger patients. The incidence rate of major bleeding episodes following warfarin therapy was twice as high in patients aged 65 and older than in younger patients. The risk for developing excessive anticoagulation is particularly high in the initial phases of therapy. Elderly patients also have a predisposition to receive polypharmacotherapy due to multisystem disease, and they often use warfarin concomitantly with many other drugs.

Therefore, it is important to know which drugs patients are taking concomitantly with warfarin. This should be taken into account by general practitioners since they have the most comprehensive overview of the treatment regimen of the patient.

In Estonia, warfarin is widely prescribed by general practitioners to prevent and treat thromboembolic diseases. To date, there has been no systematic analysis of warfarin complications or the potential risk of its interactions with other drugs in the outpatient population in Estonia. The aim of the study was to analyze the incidence of potential interactions in the prescription schemes in Estonia in a cohort of outpatients receiving warfarin treatment.

METHODS

In a retrospective prevalence study, the data of the Estonian Health Insurance Fund concerning prescriptions redeemed in the first 6 months of 2008 were analyzed. The Estonian Health Insurance Fund is the main health insurance provider and covers about 95% of the population of Estonia. All the data acquired from the Estonian Health Insurance Fund was coded. The data included outpatients of both gender aged 50 and older who had received two or more prescriptions of systemic drugs with an intended duration of treatment of a minimum of 7 days during a period of 6 months. The number of patients included in the database was 203,646, comprising 43.1% of the Estonian population aged 50 and over.

Patients who were prescribed only one pharmaceutical product or topically applied drugs were not included in the database. Those patients who had received treatment for less than 7 days were also excluded from the study. The purchase date of the drug was regarded as the start of therapy and the number of defined daily doses (DDDs) determined the duration of therapy.

Patients (n=7,175) who were prescribed warfarin therapy were further identified and analyzed separately. For patients receiving warfarin therapy, the average number of concomitantly used drugs in different age and gender groups was calculated. Potential interactions of the drugs taken were identified using the domestic drug interaction database, KIS (Koostoime Infomüürianne eesti keeles). This database, developed in Estonia by S. Uibokand and A. Zharkovsky, is currently being used as an instrument for the detection of potential interactions in prescription schemes in Estonian pharmacies.

The database is organized by potential interactions of drug pairs. The KIS database uses a risk-rating classification of interactions based on previously published criteria, outlines the possible clinical manifestation of the interaction, and gives recommendations for further actions (e.g. that the concomitant use of a specific drug pair should be avoided or that certain clinical parameters should be monitored).

The data obtained on potential interactions were further verified using two additional interaction databases: Epocrates online and Stockley’s Drug Interactions. Epocrates online is a database widely used by physicians, and according to current literature, it demonstrates a high level of validity. To our knowledge, the most comprehensive source of information on drug interactions is Stockley’s handbook, which was therefore chosen as a major source of information.

Potential interactions were taken into account only if present in all three databases. The number of potential interactions in the treatment regimen of each patient was identified.

In cases where a patient underwent several courses of the same drug combination, it was counted only once in this study.
Older patients are likely to receive polypharmacy and therefore, potentially subject to additional interactions, which do not involve warfarin-related interactions and might also have an impact on the development of adverse reactions. As a recent study\textsuperscript{22} showed, a linear increase in the number of drugs consumed led to an exponential increase in the number of adverse reactions. Therefore, drug interactions, not related to warfarin were also taken into account.

Statistical analysis was performed using SAS software. The mean standard deviation (SD) was calculated and comparisons were made using Tukey’s test. Linear correlation coefficients and Spearman’s correlation coefficients were calculated.

The study was approved by the Ethics Review Committee (ERC) on Human Research of the University of Tartu.

RESULTS

The whole database consisted of 203,646 patients. Over the 6-month inclusion period (Jan-June 2008), these patients received 1,936,961 prescriptions and 698,127 of them were for drugs that were used systemically and concomitantly. A total of 7,175 (3.5%) patients were receiving warfarin therapy, and they were given 34,903 prescriptions.

The distribution of the patients receiving warfarin treatment by age and gender is shown in Table 1. The mean number of concomitantly used drugs was 4.8 (SD=1.9) per patient. Women tended to use more drugs concomitantly, and they had slightly more drugs concomitantly, and they had slightly more drugs concomitantly than men with an OR=1.21 [95%CI 1.06:1.35]. The odds of exposure to a potential interaction among warfarin users were the highest in the reference group, the odds of exposure were greater in younger patients than in men with an OR=1.20; 95% CI 1.06:1.35. The odds of exposure to a potential interaction among warfarin users were the highest in the reference group, the odds of exposure were greater in younger patients than in men with an OR=1.20; 95% CI 1.06:1.35.

No potential interactions in treatment regimens were found in 2,713 patients (38%), and these patients had the lowest number of concomitantly used drugs: 3.6 (SD=1.33) (Table 2). One potential interaction was observed in 29% of patients and two or more potential interactions in 33% of patients (Table 2). The highest number of interactions was 13 in one patient. Over half (57%) of patients had potential interactions, related to warfarin and the number of interactions related to warfarin per patient varied from 1 to 5. Drug interactions not related to warfarin were detected in 5% of patients receiving warfarin treatment. The most common warfarin-related interaction was with non-steroidal anti-inflammatory drugs (NSAIDs) (14% of warfarin-using patients), followed by simvastatin (9%), amiodarone (7%), propafenone (5%), allopurinol (4%) and amirilidine (4%) (Table 3). The interactions not related to warfarin (5%) included beta-blocking agents and anti-diabetic drugs and the combination of NSAIDs with diuretics and ACE inhibitors.

Our study showed a positive correlation between the potential interactions and the number of concomitant drugs (Pearson correlation coefficient 0.985, p<0.0001). Multifactorial analysis did not reveal any additional associations between the number of interactions and gender and age.

Logistic regression analysis showed that, using the patient population of 50–60 years of age as a reference group, the odds of exposure to a potential interaction among warfarin users were the highest in the 61–70 years age group [OR=1.20; 95% CI 1.06:1.35].

Table 1. Mean number of drugs (including warfarin) and potential interactions among warfarin users by age and gender.

<table>
<thead>
<tr>
<th>Age</th>
<th>50-60</th>
<th>61-70</th>
<th>71-80</th>
<th>80+</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>All patients</td>
<td>1383</td>
<td>2663</td>
<td>2617</td>
<td>512</td>
<td>7175</td>
</tr>
<tr>
<td>Number of drugs (SD)</td>
<td>4.5 (1.9)*</td>
<td>4.9 (2.0)</td>
<td>4.9 (2.0)</td>
<td>4.7 (1.9)</td>
<td>4.8 (1.9)</td>
</tr>
<tr>
<td>Number of potential interactions (SD)</td>
<td>1.1 (1.3)*</td>
<td>1.3 (1.4)</td>
<td>1.3 (1.4)</td>
<td>1.0 (1.2)</td>
<td>1.2 (1.4)</td>
</tr>
<tr>
<td>Men</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Number of drugs (SD)</td>
<td>4.5 (1.9)</td>
<td>4.8 (2.1)</td>
<td>4.7 (1.9)</td>
<td>4.6 (1.9)</td>
<td>4.7 (2.0)</td>
</tr>
<tr>
<td>Number of potential interactions (SD)</td>
<td>1.2 (1.3)</td>
<td>1.2 (1.4)</td>
<td>1.1 (1.4)</td>
<td>1.0 (1.2)</td>
<td>1.2 (1.4)</td>
</tr>
<tr>
<td>Women</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Number of drugs (SD)</td>
<td>4.0 (2.0)</td>
<td>5.0 (2.0)</td>
<td>5.0 (2.0)</td>
<td>4.7 (1.9)</td>
<td>4.9 (2.0)</td>
</tr>
<tr>
<td>Number of potential interactions (SD)</td>
<td>1.1 (1.3)</td>
<td>1.4 (1.4)</td>
<td>1.3 (1.5)</td>
<td>1.1 (1.2)</td>
<td>1.3 (1.4)</td>
</tr>
</tbody>
</table>

*p<0.05 as compared with other age groups (Tukey test)

Table 2. Mean number of drugs and potential interactions among warfarin users.

<table>
<thead>
<tr>
<th>Number of potential interactions</th>
<th>Number of patients</th>
<th>Number of drugs</th>
<th>Mean (SD)</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>2713</td>
<td>3.6 (1.3)</td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>2114</td>
<td>4.7 (1.6)</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>1229</td>
<td>5.6 (1.7)</td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>604</td>
<td>6.4 (1.8)</td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>283</td>
<td>7.1 (1.7)</td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>144</td>
<td>7.8 (2.0)</td>
<td></td>
</tr>
<tr>
<td>6</td>
<td>50</td>
<td>8.4 (2.0)</td>
<td></td>
</tr>
<tr>
<td>7</td>
<td>22</td>
<td>9.1 (2.0)</td>
<td></td>
</tr>
<tr>
<td>8</td>
<td>8</td>
<td>10.0 (2.7)</td>
<td></td>
</tr>
<tr>
<td>9</td>
<td>3</td>
<td>12.7 (3.1)</td>
<td></td>
</tr>
<tr>
<td>10</td>
<td>4</td>
<td>11.3 (1.5)</td>
<td></td>
</tr>
<tr>
<td>13</td>
<td>1</td>
<td>14.0 (0.0)</td>
<td></td>
</tr>
</tbody>
</table>

DISCUSSION

For the first time, the occurrence of potential interactions in the treatment regimens of patients receiving warfarin therapy was studied in Estonia. Our study shows that of 7,175 patients, 57% had potential interactions related to warfarin and 5% of patients had interactions not related to warfarin. The number of potential interactions of warfarin-related drugs increased with the age of the patient, being lowest in the 50–60 age group: 4.5 (SD=1.9) compared with other age groups (Table 1).

Gavronski M, Hartikainen S, Zharkovsky A, Sautenkova N. Analysis of potential interactions between warfarin and other drugs among warfarin users by age and gender.
interactions increased in parallel with the number of prescriptions. A strong positive correlation between the number of drugs used and number of potential interactions underscores the need to minimize the number of drugs in the treatment regimen and to avoid drugs with potential interactions. Analysis of the literature shows a great variability in the incidence of potential interactions in patients receiving warfarin treatment.

Some studies have reported a much higher incidence of potential drug interactions in treatment schemes. In a study by Verhovsek et al., 79% of 107 long-term care patients receiving warfarin treatment had interacting drugs in their treatment schemes. This study revealed 5 most common warfarin interacting drugs: acetaminophen, citalopram, acetylsalicylic acid, diltiazem and simvastatin. The higher occurrence of potential interactions in that study is probably due to the older population of the included patients. Kotirum et al. evaluated the frequency of potential interactions in patients treated with warfarin in Thailand from June 1999 to August 2004 and also demonstrated a higher percentage of warfarin-related interactions, which occurred in 83.6% of patients. The higher percentage of potential interactions in that study may be related to the fact that over-the-counter (OTC) medicines (ibuprofen and aspirin) were included. In Estonia, aspirin and ibuprofen (400 mg) are sold without prescription. Therefore, the size of the group of patients in our study, which concomitantly uses warfarin and NSAIDs, is likely underestimated. Also, in the study by Kotirum et al., the most frequent interacting drug was paracetamol, which in Estonia is sold without prescription.

Our study shows that, in Estonia, women receiving warfarin are prescribed a higher number of medications: 4.9 (SD=2.0) compared to men: 4.7 (SD=2.0) and at the same time they have a slightly higher number of potential interactions than men. This is consistent with a previous study, in which female gender and polypharmacy increased the risk of bleeding caused by anticoagulant therapy.

Our analysis shows that 95% of patients who have interacting drugs in the treatment regimen have an increased risk of bleeding. It is important to draw attention to the interaction of NSAIDs and warfarin, which is considered to be one of the most important interactions in clinical practice. In our study, the most frequent possible interaction with warfarin was NSAIDs, which accounted for 14% of patients and 24% of interactions related to warfarin. This drug combination has been reported to increase the risk of bleeding by 2–5 times, in comparison to warfarin alone. Narum et al. studied 289 bleeding event case reports in Norway and found that in more than 50% of cases, the patients used medicines potentially interacting with warfarin. In a study on the prevalence of potentially hazardous interactions among Australian veterinarians, Roughead et al. found that 7.2% cases, which is less than in our study. In some studies, the percentage of patients who concomitantly used warfarin and NSAID, was higher in comparison to our study. In the study of Snaith et al., the prevalence of combination NSAID and warfarin was 21%. The Thai study by Kotirum et al. (1,093 patients treated with warfarin from June 1999 to August 2004) showed that 43% of patients receiving warfarin treatment also used NSAIDs.

Increased risk of bleeding is associated not only with concomitant use of warfarin with NSAIDs, but also with other drugs. Analysis of the treatment regimens in our study shows that a considerable proportion of patients concomitantly used warfarin with simvastatin (9%), amiodarone (7%), propafenone (5%) allopurinol (4%), and levothyroxine (4%). These combinations also might result in an increased risk of bleeding. The literature describing warfarin and simvastatin interactions is limited to a few case reports. Simvastatin is a substrate for CYP3A4 and may potentially interact with warfarin metabolism through competitive inhibition of the enzyme. A previous study showed that patients co-treated with statins had lower plasma 10-hydroxysteroidalwarfarin concentrations, which indicates that they had slower metabolism of (R)-warfarin. The same study, however, failed to demonstrate any significant effect of simvastatin or lovastatin on the clearance of (R)-warfarin. Therefore, the impact of statins on the pharmacokinetics of warfarin remains unclear. To avoid a possible mild risk of interaction, simvastatin could be replaced by atorvastatin, which does not interact with warfarin pharmacokinetics.

The frequency of the concomitant use of simvastatin with warfarin in other studies varied from 2.6% to 10%. In our study, the frequency of concomitant use of amiodarone (7%) was also higher than in other studies. Previous publications demonstrated that amiodarone augments the effects of warfarin via inhibition of warfarin elimination, especially in the initial phase of concomitant use of drugs, and this interaction is considered to be clinically significant. In contrast, Hermann et al. showed that there were no statistically significant differences in the concentration of 10-hydroxy-warfarin between two groups of patients who received warfarine alone or warfarin with amiodarone. It is important to note that the patients in the study of Herman et al. were treated with low doses of amiodarone, whereas the drug interacts with warfarin in a dose-dependent manner.

Other co-administered drugs among our patients on warfarin treatment were propafenone (5%), allopurinol (4%), levothyroxine (4%), which can also affect warfarin pharmacokinetics and thereby increase the risk of bleeding. It was shown that co-administration of propafenone with warfarin increased warfarin concentration by 38% in healthy volunteers. Therefore, warfarin dose must be reduced in this combination. Allopurinol in the usual clinical dosages does not affect the concentration of warfarin. Most probably the clinical significance of the interaction between warfarin and allopurinol is low. There is little data available on warfarin and levothyroxine interactions. Levothyroxine may inhibit warfarin metabolism or decrease protein binding of warfarin.
the drug; and therefore this interaction is considered to be clinically significant. Our study shows that some patients also used a drug that can induce a reduction of warfarin efficacy. The only such drug in our study, which could decrease the efficacy of warfarin, was carbamazepine, which was used by 1% of warfarin-using patients. Carbamazepine acts as a cytochrome P450 enzyme inducer and may increase the metabolism of warfarin. Herman et al. found significantly higher clearance of the (S)- and (R)-warfarin when patients used warfarin with carbamazepine. These patients also required higher doses of warfarin for desired anticoagulant effect. Kotirum et al. consider the clinical significance of this interaction as potentially high. Our study shows that 4.2% of patients on warfarin therapy also received amitriptyline. There are few articles about the co-administration of amitriptyline with an anticoagulant, but some authors have described the fluctuation of the INR values in response to this combination. The clinical significance of this interaction is unclear. Our analysis was based upon prescriptions, and therefore our study method did not address the following questions: 1) the compliance of the patients – whether the patients took the prescribed drugs and whether they followed their treatment regimen; 2) the use of non-prescription drugs. As discussed above, it is not known whether the patients were using acetaminophen for pain relief or low-dose aspirin for antithrombotic prevention, or other non-prescription drugs and herbal medicines; 3) the consumption of alcohol, tobacco and food rich in vitamin K; 4) the INR values of patients and clinically manifested adverse reactions. Not all potential interactions are manifested clinically, depending upon several patient-related factors: age, concomitant diseases, and gender. In order to address the above limitations, the current research is being continued with an analysis of patients’ case report forms. A questionnaire has also been developed concerning the drugs used and clinical interactions. According to our preliminary data, minor bleeding incidents are evident in 15% of cases of warfarin-NSAID co-administration.

CONCLUSIONS
The data obtained in this study show that 57% of outpatients in Estonia receiving warfarin are also prescribed drugs potentially interacting with warfarin and 5% of patients on warfarin have other interacting drug combinations in their treatment schemes. A strong correlation was found between the number of concomitantly used drugs and the number of potential interactions, which indicates that practicing doctors do not always consider possible interactions when establishing a treatment regimen for their patients. Most interactions with warfarin are associated with increased risk of bleeding, especially with NSAIDs (14%), followed by simvastatin (9%), amiodarone (7%), propafenone (5%), allopurinol (4%) and levothyroxine (4%). Of potential drugs, that can reduce the efficacy of warfarin, only carbamazepine was found in the included treatment regimens. Our study shows that a considerable number of outpatients receiving warfarin therapy are prescribed interacting drugs, and most of them lead to an increased risk of bleeding. This study aims to draw attention to the importance of acknowledging that drug interactions are very common in ambulatory practice. For patients in whom the use of a combination of interacting drugs cannot be avoided, a careful monitoring of adverse events should be continuously conducted. Patients on warfarin should also be instructed to avoid using over-the-counter medicines by both general practitioners and pharmacists.

ACKNOWLEDGEMENTS
We thank the Estonian Health Insurance Fund and the State Agency of Medicines for assistance with data collection and Siim Ulbokand, Rauno Vin and Joosep Lassmann for statistical analysis of the data. This research was supported by the European Union through the European Regional Development Fund of Estonia and Estonian Research Foundation Grant No. 7955.

CONFLICT OF INTEREST
None to declare.

This research was supported by the European Union through the European Regional Development Fund of Estonia and Estonian Research Foundation Grant No. 7955.

References

www.pharmacypractice.org (ISSN: 1886-3655)


<table>
<thead>
<tr>
<th>Cases (% of patients)</th>
<th>Concomitant drug (% of interactions)</th>
<th>Potential adverse effects</th>
<th>Mechanism of interaction</th>
</tr>
</thead>
<tbody>
<tr>
<td>986 (14)</td>
<td>NSAID (24)</td>
<td>Excessive gastrointestinal bleeding in individual patients</td>
<td>Alteration of gastrointestinal mucosa and platelet aggregation&lt;sub&gt;15,39,44&lt;/sub&gt;</td>
</tr>
<tr>
<td>671 (9)</td>
<td>Simvastatin (16)</td>
<td>Potentiation of the anticoagulant effect of warfarin. Interaction has been clinically insignificant in the majority of patients.</td>
<td>Alteration of warfarin metabolism; inhibition of CYP3A4 isoenzyme&lt;sub&gt;8,15,31,38&lt;/sub&gt;</td>
</tr>
<tr>
<td>476 (7)</td>
<td>Amiodarone (12)</td>
<td>Potentiation of the anticoagulant effect of warfarin. Interaction occurs in the majority of patients, develops within two weeks, and lasts for a prolonged period.</td>
<td>Alteration of warfarin metabolism; inhibition of CYP isoenzymes&lt;sub&gt;8,15,30,33,39,42,43&lt;/sub&gt;</td>
</tr>
<tr>
<td>338 (5)</td>
<td>Propafenone (8%)</td>
<td>Potentiation of the anticoagulant effect of warfarin</td>
<td>Alteration of warfarin metabolism; inhibition of CYP isoenzymes&lt;sub&gt;15,36&lt;/sub&gt;</td>
</tr>
<tr>
<td>310 (4)</td>
<td>Allopurinol (8)</td>
<td>Potentiation of the anticoagulant effect of warfarin. Bleeding was described in individual patients.</td>
<td>Alteration of warfarin elimination&lt;sup&gt;17&lt;/sup&gt;</td>
</tr>
<tr>
<td>306 (4)</td>
<td>Amitriptyline (7)</td>
<td>The anticoagulant effect of warfarin can both increase and decrease.</td>
<td>Alteration of warfarin metabolism or slow gastrointestinal motility, thereby modulate warfarin absorption&lt;sup&gt;13&lt;/sup&gt;</td>
</tr>
<tr>
<td>268 (4)</td>
<td>Levothyroxine (7)</td>
<td>Potentiation of the anticoagulant effect of warfarin</td>
<td>Alteration of vitamin K metabolism&lt;sup&gt;15,26&lt;/sup&gt;</td>
</tr>
<tr>
<td>210 (3)</td>
<td>Tramadol (5)</td>
<td>Potentiation of the anticoagulant effect of warfarin</td>
<td>Interaction may be related to the CYP2D6 activity&lt;sup&gt;8,39&lt;/sup&gt;</td>
</tr>
<tr>
<td>178 (3)</td>
<td>Amoxicillin (4)</td>
<td>The anticoagulant effect of warfarin may be unexpectedly potentiated and result in bleeding.</td>
<td>Uncertain- may be suppression of vitamin K production&lt;sup&gt;13&lt;/sup&gt;</td>
</tr>
<tr>
<td>120 (2)</td>
<td>Etoricoxib, Celecoxib (3)</td>
<td>Gastrointestinal bleeding in individual patients</td>
<td>Possible pharmacokinetic interaction in people with lower CYP2C9 metabolism; displacement of warfarin from protein binding site&lt;sup&gt;31,52&lt;/sup&gt;</td>
</tr>
<tr>
<td>75 (1)</td>
<td>Carbamazepine (2)</td>
<td>Decrease of the anticoagulant effect of warfarin in individual patients</td>
<td>Induction of CYP isoenzymes&lt;sup&gt;30,44&lt;/sup&gt;</td>
</tr>
<tr>
<td>65 (&lt;1)</td>
<td>Norfloxacin, Ciprofloxacin (2)</td>
<td>The anticoagulant effect of warfarin may be unexpectedly potentiated and result in bleeding.</td>
<td>The effects of warfarin may be potentiated in individual patients.</td>
</tr>
<tr>
<td>48 (&lt;1)</td>
<td>Fluconazole, Itraconazole (1)</td>
<td>The effects of warfarin may be potentiated in individual patients.</td>
<td>Inhibition of CYP isoenzymes&lt;sup&gt;16,34&lt;/sup&gt;</td>
</tr>
<tr>
<td>26 (&lt;1)</td>
<td>Cefuroxime (&lt;1)</td>
<td>Increased risk of hypoprothrombinaemia and increased risk of bleeding. Concomitant administration with warfarin is contraindicated.</td>
<td>Vitamin K antagonism, platelet inhibition, decreasing the gut microflora&lt;sup&gt;15,55,56&lt;/sup&gt;</td>
</tr>
<tr>
<td>15 (&lt;1)</td>
<td>Azathioprine (&lt;1)</td>
<td>Inhibition of the anticoagulant effect of warfarin</td>
<td>Mechanism is unknown- may decrease the anticoagulant response to warfarin&lt;sup&gt;57&lt;/sup&gt;</td>
</tr>
<tr>
<td>10 (&lt;1)</td>
<td>Acetaminophen (&lt;1)</td>
<td>The anticoagulant effect may be potentiated with high doses of paracetamol or in case of prolonged use.</td>
<td>Inhibition of enzymes in vitamin K cycle&lt;sup&gt;9,39&lt;/sup&gt;</td>
</tr>
<tr>
<td>5 (&lt;1)</td>
<td>Testosterone (&lt;1)</td>
<td>Potentiation of the anticoagulant effect of warfarin. Bleeding might occur.</td>
<td>Mechanism is not understood. Androgens may increase destruction of clotting factors&lt;sup&gt;60&lt;/sup&gt;</td>
</tr>
<tr>
<td>4 (&lt;1)</td>
<td>Metronidazole (&lt;1)</td>
<td>Potentiation of the anticoagulant effect of warfarin. Bleeding might occur.</td>
<td>Inhibition of CYP2C9 isoenzyme&lt;sup&gt;15,31&lt;/sup&gt;</td>
</tr>
<tr>
<td>3 (&lt;1)</td>
<td>Fenofibrate (&lt;1)</td>
<td>Potentiation of the anticoagulant effect of warfarin. Bleeding might occur. Fatalities have been reported.</td>
<td>Mechanism is uncertain, displacement of warfarin from binding sites, inhibition of CYP2C9 isoenzyme&lt;sup&gt;15,32&lt;/sup&gt;</td>
</tr>
<tr>
<td>2 (&lt;1)</td>
<td>Ciprofibrate (&lt;1)</td>
<td>Potentiation of the anticoagulant effect of warfarin. Bleeding might occur.</td>
<td>Mechanism is uncertain, displacement of warfarin from binding sites, inhibition of CYP2C9 isoenzyme&lt;sup&gt;15,63&lt;/sup&gt;</td>
</tr>
<tr>
<td>2 (&lt;1)</td>
<td>Norgestimate (&lt;1)</td>
<td>Decrease of the anticoagulant effect of warfarin in individual patients</td>
<td>Mechanism not understood&lt;sup&gt;38&lt;/sup&gt;</td>
</tr>
</tbody>
</table>